Biomarkers UK 2022 – May 3-4


Erin Newburn, PhD

Erin Newburn, PhD
Sr. Director, Field Applications Scientist
Personalis, Inc.

Tuesday, May 3 | 2:55 PM BST

Personalis NeXT Platform

Enabling precision oncology with comprehensive tumor profiling solutions for tissue and liquid biopsy

  • Combining sensitive DNA and RNA sequencing with advanced analytics, ImmunoID NeXTTM provides a multidimensional view of the tumor and microenvironment
  • A melanoma cohort case study demonstrates how a composite biomarker strengthens the association with immunotherapy response
  • NeXT PersonalTM, an ultrasensitive, tumor-informed liquid biopsy assay, designed to detect molecular residual disease will be highlighted

Connect with us at Biomarkers UK 2022